NEWARK, Calif., Sept. 2, 2020 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (NASDAQ:PTGX) today announced it will host a
"PTG-300 Opportunity Update" webinar on Friday, Sept. 11, 2020, from 12 p.m. to 1:30 p.m. EDT. The event will feature
presentations on clinical needs in polycythemia vera and market
research on the potential opportunity for PTG-300. Members of the
Protagonist leadership team, as well as the following leading key
opinion leaders and PTG-300 study investigators, will present and
participate in the webinar event.
Ronald Hoffman, M.D.
Director of the Myeloproliferative Diseases Program
The Icahn School of Medicine at Mount Sinai
Srdan Verstovsek, M.D, Ph.D.
Director, Hanns A. Pielenz Clinical Research Center for
Myeloproliferative Neoplasms
MD Anderson Cancer Center
The webinar can be accessed at the link:
https://event.webcasts.com/starthere.jsp?ei=1365062&tp_key=8c8575804b
or by visiting the Investors section of the Protagonist
Therapeutics website at http://investors.protagonist-inc.com/. The
webinar will be archived and made available following the
event.
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical stage biopharmaceutical
company that utilizes a proprietary technology platform to discover
and develop novel peptide-based therapeutics to address significant
unmet medical needs and transform existing treatment paradigms for
patients. The Company currently has three clinical-stage assets.
PTG-300 is an injectable hepcidin mimetic in development for the
treatment of polycythemia vera and other blood disorders. PTG-200
is an orally delivered, gut-restricted, interleukin-23 receptor
specific antagonist peptide in development for the treatment of
inflammatory bowel disease, with Crohn's disease as the initial
indication. The Company has a worldwide license and collaboration
agreement with Janssen Biotech, Inc., for the development of
PTG-200. PN-943 is an orally delivered, gut-restricted
alpha-4-beta-7 integrin specific antagonist peptide in development
for the treatment of inflammatory bowel disease, with ulcerative
colitis as the initial targeted indication.
Protagonist is headquartered in Newark, California. For further information,
please visit http://www.protagonist-inc.com.
View original
content:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-host-ptg-300-opportunity-update-webinar-301123273.html
SOURCE Protagonist Therapeutics, Inc.